150 related articles for article (PubMed ID: 36937957)
1. Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with
Ipe A; Angiolillo A; Jacobsohn D; Cheng J; Bornhorst M; Turner J; Vatsayan A
Front Pediatr; 2023; 11():1067131. PubMed ID: 36937957
[TBL] [Abstract][Full Text] [Related]
2. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
[TBL] [Abstract][Full Text] [Related]
3. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.
Chen L; Xu B; Long X; Gu J; Lou Y; Wang D; Cao Y; Wang N; Li C; Wang G; Wang Y; Zhu L; Wang J; An H; Xiao M; Xiao Y; Zhou J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345625
[TBL] [Abstract][Full Text] [Related]
4. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
Stubbins RJ; Korotev S; Godley LA
Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
[TBL] [Abstract][Full Text] [Related]
6. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
Barsan V; Li Y; Prabhu S; Baggott C; Nguyen K; Pacenta H; Phillips CL; Rossoff J; Stefanski H; Talano JA; Moskop A; Baumeister S; Verneris MR; Myers GD; Karras NA; Cooper S; Qayed M; Hermiston M; Satwani P; Krupski C; Keating A; Fabrizio V; Chinnabhandar V; Kunicki M; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
EClinicalMedicine; 2023 Nov; 65():102268. PubMed ID: 37954907
[TBL] [Abstract][Full Text] [Related]
7. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
Laetsch TW; Maude SL; Balduzzi A; Rives S; Bittencourt H; Boyer MW; Buechner J; De Moerloose B; Qayed M; Phillips CL; Pulsipher MA; Hiramatsu H; Tiwari R; Grupp SA
Leukemia; 2022 Jun; 36(6):1508-1515. PubMed ID: 35422096
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
[TBL] [Abstract][Full Text] [Related]
9. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
[TBL] [Abstract][Full Text] [Related]
10. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
[TBL] [Abstract][Full Text] [Related]
11. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
12. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
13. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
14. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
[TBL] [Abstract][Full Text] [Related]
16. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
Halford Z; Anderson MK; Bennett LL; Moody J
Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
18. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
19. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
Liu Y; Chen X; Han W; Zhang Y
Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA
Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
